drugset
drugset / Trial / NCT07217184

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM

NCT07217184 ↗

Phase 1/2 Active not recruiting 30 enrolled GlaxoSmithKline
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with isatuximab, and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).

Timeline

Start
2021-07-29
Primary completion
2025-04-17
Completion
2027-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Belantamab mafodotin Monoclonal antibody — —
Subject Isatuximab Monoclonal antibody — —

Indications

plasma cell myeloma